Michael Benson, MD
Urology · Belleville, NJNPI 1952720369
Payments from drug & device makers
Across 98 payments — averaging $54.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Axonics, Inc.$945
- Kerecis Limited$561
- Medtronic$401
- Johnson & Johnson$232
- Astellas Pharma US Inc$214
- plus $1K from 23 others
Across 1 payment — averaging $355.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$355
What the payments were for
- Food & beverage$5,21997%
- Education$1653%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 30 | $1,558 |
| Axonics, Inc. | 15 | $945 |
| Kerecis Limited | 3 | $561 |
| Medtronic | 6 | $401 |
| Johnson & Johnson | 4 | $232 |
| Astellas Pharma US Inc | 9 | $214 |
| Intuitive Surgical | 1 | $188 |
| Procept Biorobotics Corporation | 1 | $145 |
| Profound Medical Corp. | 1 | $145 |
| Coloplast | 1 | $144 |
| AstraZeneca | 1 | $133 |
| Conmed Corporation | 1 | $130 |
| Bayer | 5 | $110 |
| Chiesi USA, Inc. | 2 | $105 |
| Koelis Inc. | 1 | $99 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $52 |
| Endo Pharmaceuticals Inc. | 3 | $38 |
| Photocure Inc | 1 | $22 |
| Coopersurgical, Inc. | 1 | $19 |
| Endo USA, Inc. | 1 | $16 |
| Urogen Pharma, Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Urovant Sciences Inc | 1 | $14 |
| Dendreon Pharmaceuticals LLC | 1 | $14 |
| Pfizer | 1 | $14 |
| Tolmar Pharmaceuticals, Inc. | 1 | $13 |
| Abbott | 1 | $13 |
| Royal Biologics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis Omega3 Marigen$1,583
- Kerecis Omega3 SurgiClose$464
- GENERAL ERECTILE DYSFUNCTION$393
- Bulkamid$377
- Axonics$377
- GREENLIGHT$307
- Kerecis Omega3 GraftGuide$274
- INTERSTIM$247
- Da Vinci Surgical System$188
- AquaBeam Robotic System$145
- Tulsa-Pro$145
- ANDEXXA$133
- AIRSEAL$130
- Erleada$117
How this compares
$5,384 in reported general payments places this provider in the 70th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 305 | $186,441 |
| Estradiol | 192 | $11,896 |
| Solifenacin Succinate | 201 | $9,096 |
| GemtesaVibegron | 12 | $8,467 |
| Tamsulosin Hcl | 465 | $6,736 |
| Dutasteride | 142 | $5,497 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 183 | $4,308 |
| Tolterodine Tartrate ErTolterodine Tartrate | 64 | $3,117 |
| Potassium Citrate ErPotassium Citrate | 24 | $2,768 |
| Trospium Chloride | 57 | $2,765 |
| Silodosin | 19 | $1,827 |
| Oxybutynin Chloride ErOxybutynin Chloride | 56 | $1,651 |
| Finasteride | 137 | $1,379 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 30 | $630 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 20 | $465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $214 | $186,441305 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $16 | $8,46712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 401 urology providers in New Jersey.
Other urology in Belleville
- Gordon BrownCherry Hill$2.8M
- Nitin YerramHackensack$1.6M
- Michael StifelmanHackensack$1.5M
- Thomas MuellerLinwood$1.2M
- David SussmanLinwood$833K
- Michael IngberDenville$607K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$464K
- Neil ShermanCranford$404K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.